Patients reported biweekly to the clinic for CD4 T lymphocyte counts, HIV RNA estimation, and ADEs. Evaluation of the tumor response took place after 16 weeks' 9-CRA therapy in 52 patients. 8 Ten other nonevaluable patients received 9-CRA for less than 16 weeks. One patient stopped after the diagnosis of a brain lesion, unrelated to test drug. The test drug, 9-CRA, shows efficacy in AKS patients.
Efficacy occurs in the absence of antiviral activity and confounding by antiviral agents.